Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain

FEBS Journal

Volumn , Issue , 2016, Pages 3408-3437

  Iyer, Divyaanka ^a   Vartak, Supriya V ^a   Mishra, Archita ^a   Goldsmith, Gunaseelan ^b   Kumar, Sujeet ^c   Srivastava, Mrinal ^a   Hegde, Mahesh ^a   Gopalakrishnan, Vidya ^a,b   Glenn, Mark ^d   Velusamy, Mahesh ^b   Choudhary, Bibha ^b   Kalakonda, Nagesh ^d   Karki, Subhas S ^c   Surolia, Avadhesha ^a   Raghavan, Sathees C ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

^b Institute of Bioinformatics and Applied Biotechnology   (India)

^c A Constituent Unit of KLE Academy of Higher Education Research   (India)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

apoptosis; cancer therapeutics; cell death; chemotherapy; genomic instability; leukemia; molecular docking; small molecule inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; BCL2 RELATED PROTEIN A1; DISARIB; PROTEIN BCL 2; PROTEIN BCL XL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BH1 DOMAIN; BH3 DOMAIN; BINDING AFFINITY; CANCER CELL LINE; CHEMOSENSITIVITY; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DELETION MUTANT; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; EMBRYO; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION;

EID: 84987941926     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13815     Document Type: Article

References (58)

1. Cotter TG (2009) Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 9, 501–507.
2. Ferri KF & Kroemer G (2001) Organelle-specific initiation of cell death pathways. Nat Cell Biol 3, E255–E263.
3. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, Ierino H, Lee EF, Fairlie WD, Bouillet P et al. (2007) Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315, 856–859.
4. Gross A, McDonnell JM & Korsmeyer SJ (1999) BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13, 1899–1911.
5. Lin Y, Fukuchi J, Hiipakka RA, Kokontis JM & Xiang J (2007) Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage. Cell Res 17, 531–536.
6. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud JP & Guyotat D (1993) High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81, 3091–3096.
7. Kirkin V, Joos S & Zornig M (2004) The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 1644, 229–249.
8. Reed JC (1997) Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 34, 9–19.
9. Cho HJ, Kim JK, Kim KD, Yoon HK, Cho MY, Park YP, Jeon JH, Lee ES, Byun SS, Lim HM et al. (2006) Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett 237, 56–66.
10. Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Zhao S, Lopez-Berestein G & Andreeff M (2000) Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 95, 3929–3938.
11. Gutierrez-Puente Y, Zapata-Benavides P, Tari AM & Lopez-Berestein G (2002) Bcl-2-related antisense therapy. Semin Oncol 29, 71–76.
12. Wang JL, Zhang ZJ, Choksi S, Shan S, Lu Z, Croce CM, Alnemri ES, Korngold R & Huang Z (2000) Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res 60, 1498–1502.
13. Shangary S & Johnson DE (2002) Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax oligomerization, induction of cytochrome c release, and activation of cell death. Biochemistry 41, 9485–9495.
14. Arkin M (2005) Protein-protein interactions and cancer: small molecules going in for the kill. Curr Opin Chem Biol 9, 317–324.
15. Real PJ, Cao Y, Wang R, Nikolovska-Coleska Z, Sanz-Ortiz J, Wang S & Fernandez-Luna JL (2004) Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2. Cancer Res 64, 7947–7953.
16. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S et al. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10, 389–399.
17. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ et al. (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19, 202–208.
18. Wang Z, Azmi AS, Ahmad A, Banerjee S, Wang S, Sarkar FH & Mohammad RM (2009) TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. Cancer Res 69, 2757–2765.
19. Zhai D, Jin C, Satterthwait AC & Reed JC (2006) Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 13, 1419–1421.
20. Iyer D (2013) Targeted Cancer Therapy: The Role of BCL2 Inhibitors. Studium Press, LLC, Houston, TX.
21. Beauchard A, Laborie H, Rouillard H, Lozach O, Ferandin Y, Le Guevel R, Guguen-Guillouzo C, Meijer L, Besson T & Thiery V (2009) Synthesis and kinase inhibitory activity of novel substituted indigoids. Bioorg Med Chem 17, 6257–6263.
22. Mologni L, Rostagno R, Brussolo S, Knowles PP, Kjaer S, Murray-Rust J, Rosso E, Zambon A, Scapozza L, McDonald NQ et al. (2010) Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem 18, 1482–1496.
23. Wang LL, Li JJ, Zheng ZB, Liu HY, Du GJ & Li S (2004) Antitumor activities of a novel indolin-2-ketone compound, Z24: more potent inhibition on bFGF-induced angiogenesis and bcl-2 over-expressing cancer cells. Eur J Pharmacol 502, 1–10.
24. Kumar TS, Kari V, Choudhary B, Nambiar M, Akila TS & Raghavan SC (2010) Anti-apoptotic protein BCL2 down-regulates DNA end joining in cancer cells. J Biol Chem 285, 32657–32670.
25. Lotem J & Sachs L (1995) Regulation of bcl-2, bcl-XL and bax in the control of apoptosis by hematopoietic cytokines and dexamethasone. Cell Growth Differ 6, 647–653.
26. Trott O & Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31, 455–461.
27. Vedadi M, Niesen FH, Allali-Hassani A, Fedorov OY, Finerty PJ Jr, Wasney GA, Yeung R, Arrowsmith C, Ball LJ, Berglund H et al. (2006) Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc Natl Acad Sci USA 103, 15835–15840.
28. Niesen FH, Berglund H & Vedadi M (2007) The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc 2, 2212–2221.
29. Rosen CG & Weber G (1969) Dimer formation from 1-amino-8-naphthalenesulfonate catalyzed by bovine serum albumin. A new fluorescent molecule with exceptional binding properties. Biochemistry 8, 3915–3920.
30. Fedorov O, Marsden B, Pogacic V, Rellos P, Muller S, Bullock AN, Schwaller J, Sundstrom M & Knapp S (2007) A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci USA 104, 20523–20528.
31. Hanada M, Delia D, Aiello A, Stadtmauer E & Reed JC (1993) bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82, 1820–1828.
32. Marschitz I, Tinhofer I, Hittmair A, Egle A, Kos M & Greil R (2000) Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques. Am J Clin Pathol 113, 219–229.
33. Sharma S, Panjamurthy K, Choudhary B, Srivastava M, Shahabuddin M, Giri R, Advirao GM & Raghavan SC (2013) A novel DNA intercalator, 8-methoxy pyrimido[4′,5′:4,5]thieno (2,3-b)quinoline-4(3H)-one induces apoptosis in cancer cells, inhibits the tumor progression and enhances lifespan in mice with tumor. Mol Carcinog 52, 413–425.
34. Kolluri SK, Zhu X, Zhou X, Lin B, Chen Y, Sun K, Tian X, Town J, Cao X, Lin F et al. (2008) A short Nur77-derived peptide converts Bcl-2 from a protector to a killer. Cancer Cell 14, 285–298.
35. Kitada S, Kress CL, Krajewska M, Jia L, Pellecchia M & Reed JC (2008) Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood 111, 3211–3219.
36. Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, Deb S, Ritchie ME, Takano E, Ward T et al. (2012) Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci USA 109, 2766–2771.
37. Wlodkowic D, Skommer J & Pelkonen J (2006) Multiparametric analysis of HA14-1-induced apoptosis in follicular lymphoma cells. Leuk Res 30, 1187–1192.
38. Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME, Smyth GK, Christie M, Phillipson LJ, Burns CJ et al. (2013) Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell 24, 120–129.
39. Anderson NM, Harrold I, Mansour MR, Sanda T, McKeown M, Nagykary N, Bradner JE, Lan Zhang G, Look AT & Feng H (2014) BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines. Leukemia 28, 1145–1148.
40. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H et al. (2014) Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 4, 362–375.
41. Khaw SL, Merino D, Anderson MA, Glaser SP, Bouillet P, Roberts AW & Huang DC (2014) Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia 28, 1207–1215.
42. Karki SS, Panjamurthy K, Kumar S, Nambiar M, Ramareddy SA, Chiruvella KK & Raghavan SC (2011) Synthesis and biological evaluation of novel 2-aralkyl-5-substituted-6-(4′-fluorophenyl)-imidazo[2,1-b][1,3,4]thiadiazole derivatives as potent anticancer agents. Eur J Med Chem 46, 2109–2116.
43. el-Sherbeny MA, el-Bendary ER, el-Subbagh HI & el-Kashef HA (1997) Synthesis and cardiotonic activity of certain imidazo[2,1-b]-1,3,4-thiadiazole derivatives. Boll Chim Farm 136, 253–256.
44. Pentimalli L, Milani G & Biavati F (1975) Preparation and reactivity of imidazo[2,1-b]-1,3,4-thiadiazoles. Gazz Chim Ital 105, 777–787.
45. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS & Olson AJ (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30, 2785–2791.
46. Case DA, Babin V, Berryman JT, Betz RM, Cai Q, Cerutti DS, Cheatham TE III, Darden TA, Duke RE, Gohlke H et al. (2014) AMBER 14. University of California, San Francisco, CA.
47. Srivastava M, Hegde M, Chiruvella KK, Koroth J, Bhattacharya S, Choudhary B & Raghavan SC (2014) Sapodilla plum (Achras sapota) induces apoptosis in cancer cell lines and inhibits tumor progression in mice. Sci Rep 4, 6147.
48. Srivastava M, Nambiar M, Sharma S, Karki SS, Goldsmith G, Hegde M, Kumar S, Pandey M, Singh RK, Ray P et al. (2012) An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell 151, 1474–1487.
49. Moorthy BT, Ravi S, Srivastava M, Chiruvella KK, Hemlal H, Joy O & Raghavan SC (2010) Novel rhodanine derivatives induce growth inhibition followed by apoptosis. Bioorg Med Chem Lett 20, 6297–6301.
50. Shahabuddin MS, Nambiar M, Choudhary B, Advirao GM & Raghavan SC (2010) A novel DNA intercalator, butylamino-pyrimido[4′,5′:4,5]selenolo(2,3-b)quinoline, induces cell cycle arrest and apoptosis in leukemic cells. Invest New Drugs 28, 35–48.
51. Vogler M, Dinsdale D, Dyer MJ & Cohen GM (2013) ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br J Haematol 163, 139–142.
52. Dai H, Meng XW, Lee SH, Schneider PA & Kaufmann SH (2009) Context-dependent Bcl-2/Bak interactions regulate lymphoid cell apoptosis. J Biol Chem 284, 18311–18322.
53. Nedelkina S, Gokce I, Ridley H, Weckerle C, Magnin T, Vallette F, Pattus F, Lakey JH & Bechinger B (2008) High-yield expression and purification of soluble forms of the anti-apoptotic Bcl-x(L) and Bcl-2 as TolAIII-fusion proteins. Protein Expr Purif 60, 214–220.
54. Nambiar M & Raghavan SC (2012) Mechanism of fragility at BCL2 gene minor breakpoint cluster region during t(14;18) chromosomal translocation. J Biol Chem 287, 8688–8701.
55. Kavitha CV, Choudhary B, Raghavan SC & Muniyappa K (2010) Differential regulation of MRN (Mre11-Rad50-Nbs1) complex subunits and telomerase activity in cancer cells. Biochem Biophys Res Commun 399, 575–580.
56. Chiruvella KK, Kari V, Choudhary B, Nambiar M, Ghanta RG & Raghavan SC (2008) Methyl angolensate, a natural tetranortriterpenoid induces intrinsic apoptotic pathway in leukemic cells. FEBS Lett 582, 4066–4076.
57. Kavitha CV, Nambiar M, Ananda Kumar CS, Choudhary B, Muniyappa K, Rangappa KS & Raghavan SC (2009) Novel derivatives of spirohydantoin induce growth inhibition followed by apoptosis in leukemia cells. Biochem Pharmacol 77, 348–363.
58. Kavitha CV, Nambiar M, Narayanaswamy PB, Thomas E, Rathore U, Ananda Kumar CS, Choudhary B, Rangappa KS & Raghavan SC (2013) Propyl-2-(8-(3,4-difluorobenzyl)-2′,5′-dioxo-8-azaspiro[bicyclo[3.2.1] octane-3,4′-imidazolidine]-1′-yl) acetate induces apoptosis in human leukemia cells through mitochondrial pathway following cell cycle arrest. PLoS One 8, e69103.